Article

Chronotype: A Tool to Screen Eating Habits in Polycystic Ovary Syndrome?

Luigi Barrea 1,2,†, Ludovica Verde 2,4,*, Claudia Vetrani 3,*, Silvia Savastano 2,3,*, Annamaria Colao 2,3,4, and Giovanna Muscogiuri 2,3,4,*

1 Dipartimento di Scienze Umanistiche, Università Telematica Pegaso, Via Porzio, Centro Direzionale, Isola F2, 80143 Napoli, Italy; luigi.barrea@unina.it
2 Centro Italiano per la Cura e il Benessere del Paziente con Obesità (C.I.B.O), Endocrinology Unit, Dipartimento di Medicina Clinica e Chirurgia, Federico II University, Sergio Pansini, 5, 80131 Naples, Italy; ludoverde96@gmail.com (L.V.); sisavast@unina.it (S.S.); acolao@unina.it (A.C.)
3 Endocrinology Unit, Dipartimento di Medicina Clinica e Chirurgia, Federico II University, Sergio Pansini, 5, 80131 Naples, Italy; c.vetrani@libero.it
4 Cattedra Unesco “Educazione alla Salute e allo Sviluppo Sostenibile”, Federico II University, 80131 Naples, Italy
* Correspondence: giovanna.muscogiuri@gmail.com; Tel.: +39-0817463779; Fax: +30-0817463688
† These authors contributed equally to this work.

Abstract: Polycystic ovary syndrome (PCOS) is the most common endocrine disorders in women of reproductive age, whose lifestyle approach is an essential part of the treatment. Recently, chronotype, i.e., a trait that determines individual’s circadian preference in behavioral and biological rhythms, has been reported to play a role in determining nutrition preferences and the risk of developing chronic diseases. Thus, the aim of this study was to investigate if chronotype categories (morning, evening, and neither) could be used as tool to screen eating habits in women with PCOS. In this observational cross-sectional study, we assessed anthropometric measurements, lifestyle habits, chronotype categories, adherence to the Mediterranean Diet, dietary pattern, and metabolic parameters in 112 women with PCOS. Chronotype was classified as morning in 27.7%, evening in 42.9%, and neither in 29.5% of subjects. Women with PCOS with evening chronotype showed significantly higher percentages of grade I (p = 0.003) and grade II obesity (p = 0.001), did less regular exercise (p < 0.001), and most of them were smokers (p < 0.001) compared to those with neither and morning chronotypes. Women with PCOS with evening chronotype were significantly more insulin resistant (Homeostatic Model Assessment of Insulin Resistance (HoMA-IR) cut off > 2.5) than other two chronotypes (p < 0.001). Women with PCOS with evening chronotype had the lowest PREvención con DIetaMEDiterránea (PREDIMED) score, consumed more calories (p < 0.001), total fat (p < 0.001), and saturated fatty acids (p < 0.001), polyunsaturated fatty acids (p < 0.001) and n-6 polyunsaturated fatty acids (p < 0.001), and less fiber (p < 0.001) than women with PCOS with other chronotypes. In addition, women with PCOS with evening chronotype consumed less extra virgin olive oil (p = 0.001), legumes (p = 0.038), fish/seafood (p < 0.001), and tree nuts (p = 0.041) than women with PCOS of the other two chronotype categories and less red wine (p < 0.001) and more red/processed meat (p < 0.001) than women with PCOS with morning chronotype. In conclusion, women with PCOS, evening chronotype has been associated with a most severe insulin resistance and unhealthiest eating habits. Thus, chronotype assessment could be an effective tool to screen the eating habits, and more generally the lifestyle, of women with PCOS.

Keywords: PCOS; chronotype; Mediterranean diet; diet; nutrition; obesity; lifestyle

1. Introduction

Polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders in women of reproductive age reaching a prevalence rate of 5–10% [1]. Distinctive features include chronic anovulation, biochemical and/or clinical hyperandrogenism and
polycystic ovarian morphology [2]. Diagnosis of this syndrome is based on the Rotterdam criteria (2003), when 2 out of 3 criteria are satisfied, while other etiologies are excluded [2]. Hyperandrogenism is one of the main features of PCOS and evidence supports that it is one of the most used markers to assess severity of PCOS [3]. In addition, obesity, low-grade chronic inflammatory state and insulin-resistance (IR) often coexist in women with PCOS [4]. Furthermore, we also previously showed that women with PCOS had different body composition compared to women without PCOS, with the lowest values of fat free mass and phase angle (PhA), a marker of the chronic inflammatory state [5]. Beyond genetic predisposition, several pathogenetic factors could be involved in the pathogenesis of PCOS and PCOS-related complications [6,7]. In the management of women with PCOS, the crucial role of lifestyle and in particular of nutrition is well known, and it is currently at the forefront of treatment of this condition [8,9]. However, a tailored nutritional approach is based on an accurate assessment of eating habits at the baseline. The food diary is a useful tool, but it is time-consuming, and it is filled by the patients that may not objectively report eating habits. Thus, in order to drive the nutritional approach, there is the need to find an easy and valid tool to screen eating habits of PCOS in the nutrition outpatient clinic. Chronotype, i.e., the attitude of a subject determining individual circadian preference in behavioral and biological rhythms related to the external light–dark cycle, has been reported to play a role in determining nutrition preferences and the risk of developing chronic diseases [8–11]. There are three categories of chronotype: morning chronotype (defined “lark”) tends to wake up early and prefers activities earlier in the day, while the evening chronotype (defined “owl”) generally wakes up later and prefers to perform his/her main activities in the late afternoon or evening [10]. Neither chronotype is in an intermediate position between the morning and evening chronotypes [10]. Evening chronotype has been associated with a low adherence to the Mediterranean Diet (MD) [12], obesity [13], and IR [14], all of which are often present in women with PCOS [15].

Based on this background, this observational cross-sectional study aimed to investigate if chronotype categories (morning, evening, and neither) could be used as tool to screen eating habits in women with PCOS in order to drive nutritional approach.

2. Materials and Methods

2.1. Design and Setting

This cross-sectional, observational study was carried out in women with PCOS attending the Unit of Endocrinology, Department of Clinical Medicine and Surgery, University Federico II of Naples (Italy), from January 2015 to September 2021. The study was approved by the local ethics committee and carried out in accordance with the Declaration of Helsinki for human experimentation. The aim of the study was clearly explained to all study participants and written informed consent was obtained.

2.2. Population Study

After obtaining written informed consent, 300 women with PCOS (aged 18–39 years) were consecutively enrolled. To increase the homogeneity of the patient sample, we included only treatment-naïve women with PCOS. Patients with a diagnosis of PCOS according to the European Society for Human Reproduction and Embryology/American Society for Reproductive Medicine (ESHRE/ASRM) classification were eligible [2]. This includes the presence of two of the three features hyperandrogenism (either clinical (hirsutism by elevated Ferriman–Gallwey score) or biochemical (elevated testosterone or free androgen index), oligomenorrhea (interval between two menstrual periods more than 35 days), or amenorrhea (no vaginal bleeding for at least six months) and the presence of polycystic ovaries on ultrasound (≥12 follicles 2–9 mm in diameter or an ovarian volume > of 10 mL in at least one ovary) [2]. The inclusion criteria were: premenopausal women, aged 18–39 years and Body Mass Index (BMI) ranged from 21.0 to 39.9 kg/m².

Criteria for exclusion from the study were: age <18 and ≥40 years; menopause (defined as amenorrhea for ≥3 years or amenorrhea for ≥1 but <3 years and plasma follicle-
stimulating hormone concentrations elevated into the postmenopausal range); pregnancy or lactation in the last 6 months (15 women); not ovary-related hyperandrogenism and/or biochemical hyperandrogenemia, oligomenorrhea due to secondary causes according to the Endocrine Society Clinical Practice Guidelines and previous publications, including endocrine disorders (congenital adrenal hyperplasia, androgen-secreting tumors, Cushing’s syndrome, hyperprolactinemia, thyroid dysfunction, and adrenal disorders) (3 women) [16]; metabolic disorders such as type 2 diabetes (12 women), hypertension (32 women); diagnosed anemia (23 women), or other metabolic disorders requiring special diets (3 women); preexisting systemic or psychiatric diseases (8 women); use of medications that affect carbohydrate or lipid metabolism (oral contraceptives, metformin, antiepileptic drugs, antipsychotics, statins, and fish oil) (24 women); special diet plans or hypocaloric diet in the past 3 months, including vegan or vegetarian diet (41 women); supplementation with antioxidants, vitamins, or minerals (19 women); occasional or current use of medications that may affect fluid balance, including nonsteroidal anti-inflammatory drugs, diuretics, laxatives, corticosteroids, and/or antiandrogenic corticosteroids (8 women).

Therefore, a total of 112 women with PCOS remained for analysis. The flow diagram of the studied women is shown in Figure 1.

Figure 1. Flow chart of the studied women with PCOS.

2.3. Sample Size Justification and Statistical Power

The calculation of the sample size was performed a priori as, to our knowledge, there are no similar clinical studies in the literature. The calculation was carried out considering an effect size of 0.8 with a type I error of 0.05 and a power of 90% using G Power Software. The number of subjects to be enrolled was found to be 34 per group. As our sample not only reached the necessary number of subjects, but also strengthened the power of results in the statistical analysis, we decided to include all of them.
2.4. Lifestyle Habits, Nutritional Assessment, and Anthropometrical Assessment

We defined individuals who smoked at least one cigarette per day as current smokers, individuals who had quit smoking at least one year before the survey as former smokers, and the remaining participants as non-smokers. Participants who exercised at least 30 min per day (YES/NO) were defined as physically active, as we have reported in detail in previous studies [16–18]. The adherence to the MD was evaluated using the 14-items questionnaire for the assessment of PREvención con DIetaMEDiterránea (PREDIMED) [19], as previously reported [20].

From seven-day food records, we obtained the dietary histories of participants by a face-to-face interview with a nutritionist, as previously reported [5]. The total energy intake and the quantities of macronutrients has been calculated based on seven-day food records. Anthropometric measurements and biochemical and hormonal parameters were taken between 8 a.m. and 12 noon. All subjects were measured after an overnight fast. Anthropometric measurements were performed by the same operator (a nutritionist with experience in nutrition and body composition assessment) according to the International Society for the Advancement of Kinanthropometry (ISAK 2006). All anthropometric measurements were performed with subjects wearing only light clothing and no shoes, as previously reported [18,21,22]. Height was assessed to the nearest 0.5 cm using a wall stadiometer (Seca 711; Seca, Hamburg, Germany). Body weight was measured to the nearest 0.1 kg using a calibrated beam scale (Seca 711; Seca, Hamburg, Germany). In accordance with the World Health Organisation, BMI was classified as follows: normal weight: 18.5–24.9 kg/m$^2$, overweight, 25.0–29.9 kg/m$^2$; grade I obesity, 30.0–34.9 kg/m$^2$; grade II obesity, 35.0–39.9 kg/m$^2$ [23]. Waist circumference (WC) was measured to the nearest 0.1 cm with a non-extendable tape measure at the natural indentation or halfway between the lower edge of the rib cage and the iliac crest if no natural indentation was visible, according to the National Center for Health Statistics [24].

2.5. Assay Methods

Collection of samples was done between 8 and 10 am following an overnight fast of at least 8 h and stored at $-80^\circ$C until processing in the central biochemistry laboratory of our institute. Plasma glucose was analyzed using a Roche modular analytical system while fasting insulin levels were measured using a solid-phase chemiluminescent immunoassay. The Homeostasis Model Assessment of Insulin Resistance (HoMA-IR) was calculated according to Matthews et al. [25]. HoMA-IR value > 2.5 was used as cutoff value for the IR. Intra- and inter-assay values CV were <7% for all assays performed.

2.6. Chronotype Assessment

To assess the participants’ chronotype, we used the Morningness–Eveningness Questionnaire (MEQ) [10]. The MEQ consists of 19 multiple-choice questions regarding sleep habits and daily performance, such as when feeling most productive in physical or mental activities, when feeling most tired, and when feeling most energetic. The sum of the individual items produced a total score ranging from 16 to 86 and based on their score, individuals were classified as morning (59–86), neither (42–58), or evening (16–41) chronotypes [10].

2.7. Statistical Analysis

The data distribution was evaluated by Kolmogorov–Smirnov test and data not normally distributed were normalized by logarithm. The chi square ($\chi^2$) test was used to determine the significance of differences in frequency distribution of BMI categories, physical activity, smoking habit, and HoMA-IR. An ANOVA test followed by the Bonferroni post hoc test was used to evaluate the differences between three groups. The correlations between study variables were performed using Pearson $r$ correlation coefficients. A partial correlation was performed to control for effects of confounding factors on chronotype. Proportional Odds Ratio (OR) models, 95% Interval Confidence (IC), and $R^2$ were used to assess the associations among chronotype score with single items of PREDIMED ques-
tionnaire in women with PCOS. Data were collected and analyzed using the MedCalc® package (Version 12.3.0 1993-2012-Mariakerke, Belgium).

### 3. Results

One hundred and twelve women with PCOS (aged 24.21 ± 5.47 years; BMI 30.95 ± 5.66 kg/m²) were enrolled. Specifically, 24 subjects (21.4%) of them were normal weight, 29 subjects (25.9%) were overweight, and 24 subjects (21.4%) and 35 subjects (31.3%) had grade I and II obesity, respectively. The chronotype categories were distributed among women with PCOS as follows: 31 women (27.7%) morning, 33 women (29.5%) neither, and 48 women (42.9%) evening chronotype. BMI categories, lifestyle habits, and HoMA-IR of women with PCOS, according to chronotype categories, are reported in Table 1. Women with PCOS with evening chronotype showed significantly higher percentages of grade I ($p = 0.003$) and grade II obesity ($p = 0.001$) and were less prone to follow healthy lifestyles compared to those with neither and morning chronotypes; indeed, they did less regular exercise ($p < 0.001$) and most of them were smokers ($p < 0.001$). Evening chronotype also was significantly associated with a higher prevalence of subjects with HoMA-IR cut off $> 2.5$ than neither and morning chronotypes ($p < 0.001$).

#### Table 1. BMI categories, lifestyle habits, and HoMA-IR of women with PCOS according to chronotype categories.

| Parameters               | Morning Chronotype n = 31, 27.7% | Neither Chronotype n = 33, 29.5% | Evening Chronotype n = 48, 42.9% | $\chi^2$ | $p$-Value |
|--------------------------|----------------------------------|----------------------------------|----------------------------------|----------|-----------|
| BMI categories           |                                  |                                  |                                  |          |           |
| Normal weight (n, %)     | 22 (71.0)                        | 2 (6.1)                          | 0 (0)                            | 62.91    | <0.001    |
| Overweight (n, %)        | 4 (12.9)                         | 18 (54.5)                        | 7 (14.6)                         | 20.04    | <0.001    |
| Grade I obesity (n, %)   | 1 (3.2)                          | 6 (18.2)                         | 17 (35.4)                        | 11.89    | 0.003     |
| Grade II obesity (n, %)  | 4 (12.9)                         | 7 (21.2)                         | 24 (50.0)                        | 19.16    | 0.001     |
| Physical activity        |                                  |                                  |                                  |          |           |
| YES (n, %)               | 20 (64.5)                        | 13 (39.4)                        | 3 (6.3)                          | 30.45    | <0.001    |
| NO (n, %)                | 11 (35.5)                        | 20 (60.6)                        | 45 (93.8)                        |          |           |
| Smoking                  |                                  |                                  |                                  |          |           |
| YES (n, %)               | 2 (6.5)                          | 2 (6.1)                          | 25 (52.1)                        | 30.03    | <0.001    |
| NO (n, %)                | 29 (93.5)                        | 31 (93.9)                        | 23 (47.9)                        |          |           |
| HoMA-IR                  |                                  |                                  |                                  |          |           |
| $<$2.5 (n, %)            | 30 (96.8)                        | 26 (78.8)                        | 19 (39.6)                        | 30.81    | <0.001    |
| $\geq$2.5 (n, %)         | 1 (3.2)                          | 7 (21.2)                         | 29 (60.4)                        |          |           |

A $p$-value in bold type denotes a significant difference ($p < 0.05$). BMI, Body Mass Index; HoMA-IR, homeostasis model assessment-insulin resistance.

Differences in age, BMI, WC, HoMA-IR, and adherence to the MD were showed in Table 2. There were no differences in age among the chronotype categories ($p = 0.763$). Finally, women with PCOS with evening chronotype had the lowest PREDIMED score, i.e., they had the lowest adherence to the MD compared to the other chronotypes ($p < 0.001$).

Figure 2 reported adherence to the MD in women with PCOS grouped based on chronotype categories. Women with lower adherence to the MD presented the high percentage of evening chronotype (58.3%; $p < 0.001$). Of note, no women with PCOS with evening chronotype reported high adherence to the MD (0.0%; $p < 0.001$).
Table 2. Age, BMI, WC, HoMA-IR, and adherence to the MD in chronotype categories in comparison.

| Parameters                        | Mean ± SD       | p-Value |
|-----------------------------------|-----------------|---------|
| Age (years)                       | 24.58 ± 5.16 vs. 24.23 ± 6.49 | 0.763 * |
| Evening vs. morning chronotype    |                 |         |
| Evening vs. neither chronotype    | 24.58 ± 5.16 vs. 23.67 ± 4.95 | 1.000   |
| Neither vs. morning chronotype    | 23.67 ± 4.95 vs. 24.23 ± 6.49 | 1.000   |
| BMI (kg/m²)                       | 34.92 ± 3.87 vs. 25.95 ± 4.66 | <0.001 *|
| Evening vs. morning chronotype    |                 |         |
| Evening vs. neither chronotype    | 34.92 ± 3.87 vs. 29.91 ± 4.44 | <0.001 *|
| Neither vs. morning chronotype    | 29.91 ± 4.44 vs. 25.95 ± 4.66 | <0.001 *|
| WC (cm)                           | 110.71 ± 15.95 vs. 89.33 ± 12.32 | <0.001 *|
| Evening vs. morning chronotype    |                 |         |
| Evening vs. neither chronotype    | 110.71 ± 15.95 vs. 98.15 ± 11.11 | <0.001 *|
| Neither vs. morning chronotype    | 98.15 ± 11.11 vs. 89.33 ± 12.32 | 0.034   |
| HoMA-IR                           |                 |         |
| Evening vs. morning chronotype    | 4.85 ± 4.26 vs. 0.96 ± 1.69 | <0.001 *|
| Evening vs. neither chronotype    | 4.85 ± 4.26 vs. 1.9 ± 2.29 | <0.001 *|
| Neither vs. morning chronotype    | 1.9 ± 2.29 vs. 0.96 ± 1.69 | 0.709   |
| PREDIMED score                    |                 |         |
| Evening vs. morning chronotype    | 5.06 ± 1.93 vs. 9.67 ± 1.98 | <0.001 *|
| Evening vs. neither chronotype    | 5.06 ± 1.93 vs. 7.21 ± 1.95 | <0.001 *|
| Neither vs. morning chronotype    | 7.21 ± 1.95 vs. 9.67 ± 1.98 | <0.001 *|

A p value in bold type denotes a significant difference (p < 0.05). Results are expressed as the mean ± SD. BMI, Body Mass Index; HoMA-IR, homeostasis model assessment-insulin resistance; PREDIMED, Prevenciòn con Dieta Mediterrànea; and SD, standard deviation. * Differences among three groups.

**Figure 2.** Adherence to the MD according to chronotype categories in women with PCOS. A p value in bold type denotes a significant difference (p < 0.05). MD, Mediterranean diet; PREDIMED, Prevenciòn con Dieta Mediterrànea.

Table 3 reported differences in nutritional parameters of women with PCOS, according to chronotype categories. In detail, women with PCOS with evening chronotype consumed more total energy intake (p < 0.001), total and simple carbohydrates (p < 0.001), total fat, saturated fatty acids (SFA), polyunsaturated fatty acids (PUFA, and n-6 PUFA (p < 0.001 for all), and less fiber (p < 0.001) than women with PCOS with other chronotype categories.
Table 3. Differences in nutritional parameters of women with PCOS, according to chronotype categories.

| Parameters                          | Mean ± SD                      | p-Value |
|-------------------------------------|-------------------------------|---------|
| Total energy intake (kcal)          |                               | <0.001 *|
| Evening vs. morning chronotype      | 2372.77 ± 301.32 vs. 2053.19 ± 198.04 |         |
| Evening vs. neither chronotype      | 2372.77 ± 301.32 vs. 2240.39 ± 250.94 | 0.082   |
| Neither vs. morning chronotype      | 2240.39 ± 250.94 vs. 2053.19 ± 198.04 | 0.015   |
| Carbohydrate (g of total kcal)      |                               |         |
| Evening vs. morning chronotype      | 326.40 ± 45.05 vs. 280.71 ± 28.54 | <0.001  |
| Evening vs. neither chronotype      | 326.40 ± 45.05 vs. 306.79 ± 33.94 | 0.072   |
| Neither vs. morning chronotype      | 306.79 ± 33.94 vs. 280.71 ± 28.54 | 0.021   |
| Complex (g of total kcal)           |                               |         |
| Evening vs. morning chronotype      | 174.37 ± 30.59 vs. 170.23 ± 19.99 | 1.000   |
| Evening vs. neither chronotype      | 174.37 ± 30.59 vs. 177.73 ± 21.61 | 1.000   |
| Neither vs. morning chronotype      | 177.73 ± 21.61 vs. 170.23 ± 19.99 | 0.726   |
| Simplex (g of total kcal)           |                               |         |
| Evening vs. morning chronotype      | 152.03 ± 34.06 vs. 110.48 ± 20.37 | <0.001  |
| Evening vs. neither chronotype      | 152.03 ± 34.06 vs. 129.07 ± 29.53 | 0.002   |
| Neither vs. morning chronotype      | 129.07 ± 29.53 vs. 110.48 ± 20.37 | 0.040   |
| Protein (g of total kcal)           |                               |         |
| Evening vs. morning chronotype      | 13.55 ± 2.99 vs. 17.91 ± 3.61  | <0.001  |
| Evening vs. neither chronotype      | 13.55 ± 2.99 vs. 15.88 ± 3.06  | 0.004   |
| Neither vs. morning chronotype      | 15.88 ± 3.06 vs. 17.91 ± 3.61  | 0.037   |
| Fat (g of total kcal)               |                               |         |
| Evening vs. morning chronotype      | 85.86 ± 8.89 vs. 86.65 ± 9.27  | 1.000   |
| Evening vs. neither chronotype      | 85.86 ± 8.89 vs. 88.93 ± 12.43 | 0.552   |
| Neither vs. morning chronotype      | 88.93 ± 12.43 vs. 86.65 ± 9.27 | 1.000   |
| Saturated Fatty Acids; MUFA, MonoUnsaturated Fatty Acids; PUFA, PolyUnsaturated Fatty Acids; and SD, standard deviation. * Differences among three groups. |

A p value in bold type denotes a significant difference (p < 0.05). Results are expressed as the mean ± SD. SFA, Saturated Fatty Acids; MUFA, MonoUnsaturated Fatty Acids; PUFA, PolyUnsaturated Fatty Acids; and SD, standard deviation. * Differences among three groups.

Analyzing the response frequency of dietary components included in the PREDIMED questionnaire in detail, we found that, when compared to the other two chronotype categories, women with PCOS with evening chronotype consumed less extra virgin olive oil (EVOO) (p = 0.001), legumes (p = 0.038), fish/seafood (p < 0.001), and tree nuts (p = 0.041). In addition, women with PCOS with evening chronotype consumed less red wine (p < 0.001) and more red/processed meat (p < 0.001) than women with PCOS with morning chronotype (Table 4).
Correlation analyses were performed to investigate the association of chronotype scores with anthropometric measurements, metabolic, and nutritional parameters as reported in Table 5. Chronotype score was inversely associated with BMI ($r = -0.775; p < 0.001$), WC ($r = -0.674; p < 0.001$), fasting plasma glucose ($r = -0.486; p < 0.001$), insulin levels ($r = -0.568; p < 0.001$), HoMA-IR ($r = -0.556; p < 0.001$), and positively associated with PREDIMED score ($r = 0.803; p < 0.001$). In addition, the chronotype score was also inversely associated with total energy intake ($r = -0.507; p < 0.001$), total carbohydrate ($r = -0.563; p < 0.001$), simple carbohydrates ($r = -0.609; p < 0.001$), total fat ($r = -0.598; p < 0.001$), SFA ($r = -0.711; p < 0.001$), unsaturated fat ($r = -0.324; p < 0.001$), PUFA ($r = -0.465; p < 0.001$), and n-6 PUFA ($r = -0.456; p < 0.001$) and positively associated with fiber intake ($r= 0.531; p < 0.001$).

Table 4. Response frequency of dietary components included in the PREDIMED questionnaire of women with PCOS, according to chronotype categories.

| Questions PREDIMED Questionnaire | Morning Chronotype $n = 31, 27.7\%$ | Neither Chronotype $n = 33, 29.5\%$ | Evening Chronotype $n = 48, 42.9\%$ | $\chi^2$ | $p$-Value |
|----------------------------------|--------------------------------------|--------------------------------------|--------------------------------------|--------|----------|
| Use of EVOO as main culinary lipid | 29 (93.5) | 29 (87.9) | 30 (62.5) | 17.20 | 0.001 |
| EVOO > 4 tablespoons | 24 (77.4) | 18 (54.5) | 22 (45.8) | 3.51 | 0.173 |
| Vegetables $\geq$ 2 servings/day | 25 (80.6) | 17 (51.5) | 12 (25.0) | 1.55 | 0.460 |
| Fruits $\geq$ 3 servings/day | 26 (83.9) | 21 (63.6) | 20 (41.7) | 1.12 | 0.099 |
| Red/processed meats $< 1$/day | 13 (41.9) | 22 (66.7) | 27 (56.3) | 29.87 | $<0.001$ |
| Butter, cream, margarine $< 1$/day | 15 (48.4) | 16 (48.5) | 16 (33.3) | 4.02 | 0.134 |
| Soda drinks $< 1$/day | 15 (48.4) | 22 (66.7) | 16 (33.3) | 10.16 | 0.006 |
| Wine glasses $\geq$ 7/week | 19 (61.3) | 4 (12.1) | 7 (14.6) | 7.91 | 0.019 |
| Legumes $\geq$ 3/week | 20 (64.5) | 18 (54.5) | 22 (45.8) | 6.52 | 0.038 |
| Fish/seafood $\geq$ 3/week | 28 (90.3) | 7 (21.2) | 0 (0) | 32.03 | $<0.001$ |
| Commercial sweets and confectionery $\leq$ 2/week | 23 (74.2) | 20 (60.6) | 16 (33.3) | 1.28 | 0.527 |
| Tree nuts $\geq$ 3/week | 19 (61.3) | 5 (15.2) | 7 (14.6) | 6.39 | 0.041 |
| Poultry more than red meats | 26 (83.9) | 19 (57.6) | 18 (37.5) | 0.15 | 0.928 |
| Use of sofrito sauce $\geq$ 2/week | 18 (58.1) | 20 (60.6) | 30 (62.5) | 1.58 | 0.466 |

A $p$ value in bold type denotes a significant difference ($p < 0.05$). PREDIMED, Prevención con Dieta Mediterránea; EVOO, extra virgin olive oil.

Table 5. Correlations of chronotype score with studied parameters in women with PCOS.

| Parameters | Chronotype Score $n = 112$ |
|------------|--------------------------|
| Age (years) | 0.006 | 0.951 |
| Anthropometric measurement | | |
| BMI (kg/m$^2$) | $-0.775$ | $<0.001$ |
| WC (cm) | $-0.673$ | $<0.001$ |
| Metabolic, hormonal, and inflammatory profile | | |
| Fasting plasma glucose (mg/dL) | $-0.486$ | $<0.001$ |
| Insulin levels (µU/mL) | $-0.568$ | $<0.001$ |
| HoMA-IR | $-0.556$ | $<0.001$ |
| Nutritional parameters | | |
| PREDIMED score | 0.803 | $<0.001$ |
| Total energy intake (kcal) | $-0.507$ | $<0.001$ |
| Carbohydrate (g of total kcal) | $-0.563$ | $<0.001$ |
| Complex (g of total kcal) | $-0.116$ | 0.221 |
Table 5. Cont.

| Parameters                          | Chronotype Score | n = 112 | r       | p-Value |
|-------------------------------------|------------------|---------|---------|---------|
| Simple (g of total kcal)            |                  |         | −0.609  | <0.001  |
| Fiber (g/day)                       |                  |         | 0.531   | <0.001  |
| Protein (g of total kcal)           |                  |         | 0.053   | 0.576   |
| Fat (g of total kcal)               |                  |         | −0.598  | <0.001  |
| SFA (g of total kcal)               |                  |         | −0.711  | <0.001  |
| Unsaturated fat (g of total kcal)   |                  |         | −0.324  | <0.001  |
| MUFA (g of total kcal)              |                  |         | 0.088   | 0.356   |
| PUFA (g of total kcal)              |                  |         | −0.465  | <0.001  |
| n-3 PUFA (g/day)                    |                  |         | −0.035  | 0.712   |
| n-6 PUFA (g/day)                    |                  |         | −0.456  | <0.001  |

A p value in bold type denotes a significant difference (p < 0.05). BMI, Body Mass Index; WC, waist circumference; HoMa-IR, homeostasis model assessment-insulin resistance; PREDIMED, Prevención con Dieta Mediterránea; SFA, Saturated Fatty Acids; MUFA, MonoUnsaturated Fatty Acids; and PUFA, PolyUnsaturated Fatty Acids.

Table 6 showed the results of the bivariate proportional OR model performed to assess the association of chronotype score with food items of the PREDIMED questionnaire. EVOO, vegetable, fruit, fish, poultry, nuts, and wine consumption were positively associated with chronotype score, while the highest OR of soda drinks, red meats, butter, cream, margarine commercial sweets and confectionery seemed to have a negative effect on chronotype score.

Table 6. Bivariate proportional OR models performed to assess the association of chronotype score with the dietary components included in the PREDIMED questionnaire and with PREDIMED categories.

| Parameters                              | Chronotype Score | OR  | p-Value | 95% IC | R²  |
|-----------------------------------------|------------------|-----|---------|--------|-----|
| Use of EVOO as main culinary lipid      |                  | 1.08| <0.001  | 1.04–1.12 | 0.19 |
| EVOO > 4 tablespoons                    |                  | 1.04| 0.001   | 1.02–1.07 | 0.10 |
| Vegetables ≥ 2 servings/day             |                  | 1.06| <0.001  | 1.04–1.09 | 0.21 |
| Fruits ≥ 3 servings/day                 |                  | 1.05| <0.001  | 1.03–1.08 | 0.15 |
| Red/processed meats < 1/day             |                  | 0.99| 0.672   | 0.98–1.02 | 0.01 |
| Butter, cream, margarine < 1/day       |                  | 1.02| 0.076   | 0.99–1.04 | 0.03 |
| Soda drinks < 1/day                     |                  | 1.03| 0.010   | 1.01–1.05 | 0.06 |
| Wine glasses ≥ 7/week                   |                  | 1.05| <0.001  | 1.03–1.08 | 0.14 |
| Legumes ≥ 3/week                        |                  | 1.03| 0.019   | 1.00–1.05 | 0.05 |
| Fish/seafood ≥ 3/week                   |                  | 1.29| <0.001  | 1.15–1.14 | 0.57 |
| Commercial sweets and confectionery ≤ 2/week |              | 1.05| <0.001  | 1.03–1.08 | 0.17 |
| Tree nuts ≥ 3/week                      |                  | 1.06| <0.001  | 1.03–1.09 | 0.18 |
| Poultry more than red meats             |                  | 1.04| <0.001  | 1.02–1.08 | 0.16 |
| Use of sofrito sauce ≥ 2/week           |                  | 0.99| 0.769   | 0.98–1.02 | 0.01 |

A p value in bold type denotes a significant difference (p < 0.05). EVOO, extra virgin olive oil.

4. Discussion

Women with PCOS and evening chronotype had higher rates of obesity and were less prone to follow healthy lifestyle. In fact, they exercised less regularly and smoked more than women with PCOS with neither and morning chronotypes.

In agreement with our results, subjects with evening chronotype have previously been reported to be more likely to have obesity and an unhealthy lifestyle [12]. In this regard, in a cross-sectional study including 172 middle-aged adults, the lower the chronotype score, the higher the BMI values in the entire population, suggesting that obesity was a common finding in subjects with evening chronotype. Additionally, in this study, subjects with evening chronotype followed an unhealthier lifestyle (less regular activity and more frequently smokers) than other chronotype categories [12].

In our population, evening chronotype was significantly associated with a higher prevalence of IR subjects (HoMA-IR cut off > 2.5) than the other two chronotype categories.
In addition, chronotype score was inversely associated with fasting plasma glucose, insulin levels, and HoMA-IR. Evening chronotype involves a misalignment of physiological circadian rhythms [10] and it has already been reported that humans develop impaired glucose tolerance when subjected to circadian misalignment conditions [10,26–28]. As PCOS is already a risk factor for IR, evening chronotype may have an additional deleterious effect on the metabolic profile. In this regard, mutations in multiple clock genes in humans have been shown to contribute to genetic susceptibility to obesity, IR, and type 2 diabetes [10,26–28]. Indeed, the risk of developing impaired fasting plasma glucose has been associated with polymorphisms in CRY2 [10,26,28] while the polymorphism in ARNTL has been reported to increase the susceptibility to develop type 2 diabetes [27]. Similarly, having polymorphism in NR1D1 has been associated with the risk of developing obesity [29]. Based on these findings, several studies investigated gene-behavior interactions and showed that interactions between diet and clock gene mutations affect fasting plasma glucose [30], IR [31], body weight [32], and type 2 diabetes [27].

For the first time, we report that women with PCOS with evening chronotype had the lowest adherence to the MD and poorer eating habits. In addition, the lower the chronotype score, the lower the PREDIMED score in these women. Considering the nutritional parameters, women with PCOS with evening chronotype consumed more total energy intake, total and simple carbohydrates, total fat, SFA, PUFA, n-6 PUFAs, and less fiber than women with PCOS with other chronotypes. In addition, regarding the dietary components included in the PREDIMED questionnaire, we found that women with PCOS with evening chronotype consumed less EVOO, red wine, legumes, fish/seafood, and tree nuts and more red/processed meat than women with PCOS with neither and morning chronotypes.

In agreement with our results, it has been reported that subjects with obesity and evening chronotype had the lowest adherence to the MD and poorer eating habits. In fact, in the study previously mentioned, it has been also reported that evening chronotype had the highest percentage of subjects with low adherence to the MD and the lowest percentages of subjects with average and high adherence to the MD [12].

The association of chronotype categories with the adherence to the MD might be mediated by the food cluster enclosed in the MD. In fact, a high adherence to the MD could also contribute to normal sleeping pattern [33,34] that in turn plays an important role in determining the chronotype [10]. In this regard, in a cross-sectional study of 172 middle-aged adults with obesity, good sleepers (assessed by Pittsburgh Sleep Quality Index < 5) when compared to poor sleepers had significantly higher adherence to the MD [34]. In another cross-sectional study of 1936 individuals, for every point by which the MD score (MEDI-LITE score) increased, the probability of having adequate sleep quality increased by 10% [33].

It appears that eating patterns change in chronotype categories and this has already been reported previously [35,36]. In agreement with this, it has already been reported that individuals with evening chronotype tend to have a less healthy diet, with higher intakes of sugary drinks and chocolate and lower intakes of vegetables, fish, and fruit than individuals with morning chronotype [35,36]. Mota et al., in a cross-sectional study in medical residents (n = 72) evaluating chronotype and dietary patterns, found that chronotype score was negatively associated with cholesterol and sweet intake [35]. The same finding was then also confirmed in another cross-sectional study carried out in pregnant women (n= 100) [36]. In these women, the morning chronotype was associated with better diet quality [36]. Furthermore, another cross-sectional study reported that a low intake of micronutrients (vitamins and minerals) was also associated with the evening chronotype [37]. In particular, a significant association of the evening chronotype with a lower intake of protein, micronutrients (such as calcium, magnesium, zinc, and vitamins), and vegetables, and a higher intake of noodles has been detected in 112 young women [37]. A deficit of micronutrients such as vitamin D has also been often detected in women with
PCOS [6,38] and it has been associated with sleep disturbances [39], a common finding in evening chronotype.

Preference for consumption of specific foods and more generally different dietary patterns may also play a role in worsening normal circadian rhythms [40]. In this regard, it has been reported that the macronutrient composition of the diet can alter the function of central and peripheral circadian clocks in humans [36]. A well-known characteristic of the MD is high fiber content and consequently a low glycemic index (GI) [41]. Our data showed that women with PCOS with evening chronotype consumed more carbohydrates and less fiber than the same women with other two chronotype categories thus suggesting that the diet of these women is characterized by a high GI. Similarly, a recent study by Gangwish et al. carried out in a population of postmenopausal women (n = 53,069) found that high GI diets may be a risk factor for insomnia, whereas the intake of unprocessed, fiber-rich, low GI whole-grain carbohydrates such as whole grains reduced this risk [42]. Hyperinsulinemia, resulting from high glycemic load dietary intake, could result in reactive hypoglycemia, thus triggering the secretion of autonomous counter-regulatory hormones such as adrenaline and cortisol, which may cause symptoms such as heart palpitations, tremors, anxiety, and irritability causing waking from sleep [42]. Indeed, St-Onge et al. observed that a low fiber intake and a high intake of SFA and sugars in normal weight adults (n = 26) was associated with less restorative sleep resulting in reduced overall sleep quality [43]. In addition, high GI food predisposes to obesity, which is a well-known risk factor for sleep disturbances [44]. Therefore, it is possible that a high-fiber diet such as the MD may be a useful tool for improving sleep in individuals with sleep disturbances [43]. Furthermore, in a cross-sectional study of non-shift workers (n = 4435) conducted by Tanaka et al., the association among carbohydrate, lipid, and protein intake and insomnia symptoms, including difficulty initiating sleep, difficulty maintaining sleep, and poor quality of sleep was assessed [45]. This study showed that protein and carbohydrate intake were associated with insomnia; in particular, a low protein intake (19% of energy from protein) and low carbohydrate intake (50% of energy from carbohydrate) were associated with difficulty maintaining sleep. This can probably be explained by the fact that a low protein intake could lead to a low availability of tryptophan, a precursor of serotonin and melatonin, which are well known hormones promoting sleep, while a high protein intake can reduce tryptophan concentrations in the brain due to competition for the blood–brain barrier transporter with other neutral amino acids, causing in both cases symptoms of insomnia [45]. The MD contains various dietary sources of tryptophan such as milk, turkey, chicken, fish, eggs, beans, cheese, and green leafy vegetables. Thus, low adherence to the MD, as in the case of women with PCOS with evening chronotype, results in poor intake of tryptophan-rich foods. The intake of tryptophan-rich food has been associated with an improvement of primary insomnia in healthy subjects (n = 49) [46]. In this study, administration of food bars containing small dose (250 mg) of tryptophan achieved significant results in reducing waking time during the night, increasing sleep efficiency, and increasing subjective sleep quality [46]. Furthermore, the depletion of tryptophan resulted in sleep fragmentation, rapid eye movement sleep latency and rapid eye movement density compared to baseline and placebo [47,48]. Consumption of tryptophan-rich proteins (e.g., milk protein) may also improve sleep quality by influencing changes in core temperature [49].

The MD also includes a substantial consumption of fruits and clinical studies suggested sleep-promoting effects of some fruits [45–48]. In humans, consumption of two kiwis one hour before bedtime improved sleep onset, duration, and efficiency in healthy adults (n = 24) during a 4-week open clinical trial [50]. In addition, a double-blind pilot study showed that fresh tartar cherry juice reduced insomnia in elderly subjects (n = 15) [51]. The effects of cherries have also been reported to increase sleep duration and to reduce the number of awakenings, as measured by actigraphy in Spanish participants (n = 12) [52]. These benefits may be facilitated by dietary polyphenols, which have been shown to modulate circadian rhythms [53] and sleep–wake cycles in rodents [54]. According to another hypothesis, these results (on improvement of sleep quality) could probably be due to the high content
of antioxidants in fruit. In fact, antioxidants may have beneficial effects in subjects with sleep disorders as they may develop oxidative stress due to the accumulation of free radicals [55]. During sleep, the antioxidant activity increases in the whole body, resulting in the elimination of oxygen free radicals accumulated during wakefulness [55]. In addition to fruit, both polyphenols and antioxidants are also present in other foods that are typical of the MD such as EVOO and red wine that were less consumed in our population of women with PCOS with evening chronotype. In particular, it has been identified that several polyphenols, such as resveratrol, a polyphenol found in red wine, act as dietary activators of Sirtuin 1 (SIRT1) [56]. In turn, SIRT1 modulates transcription factors including period circadian clock 2 (PER2), which are circadian clock genes that in turn regulate the daily rhythms of locomotor activity, metabolism, and behavior [57]. Additionally, SIRT1 modulates the ventromedial hypothalamic clock, a brain region that contains neuronal food-synchronized clocks contributing to regulation of the circadian rhythm in feeding behavior [57]. Thus, it is possible to speculate that a high adherence to the MD and more specifically the consumption of certain foods with well-known positive effects on sleep may contribute to the maintenance of normal circadian rhythms and therefore have an influence on chronotype [10].

The main strength of our study was the novelty of highlighting the role of chronotype assessment in women with PCOS. Identifying women with PCOS and evening chronotype becomes of paramount importance because they might be at risk of following unhealthy diet thus being at high risk of developing metabolic diseases. In this context, using a tool as easy as the MEQ questionnaire, women with PCOS with a worse clinical and metabolic picture could be identified early and thus could be tackled with more tailored diet plans. Indeed, an intervention that seeks to align the attitude of the evening chronotype with the circadian time could be an early attempt to improve the metabolic status of women with PCOS. The limitation of the study is represented above all by the cross-sectional experimental design, which, although showing the association of the evening chronotype with a worsening of IR in women with PCOS, fails to provide any explanation of the causality of this association. It is recommended that future longitudinal studies investigate the causality among these variables with particular emphasis on the implementation of lifestyle interventions. Although a CLOCK-gene assessment of chronotype should be more accurate but more difficult to carry out, there are several studies that validated the association of chronotype, and thus the assessment of chronotype categories through a questionnaire, with CLOCK-gene based assessed of chronotype [58]. This allows us to use this tool for the assessment of chronotype in our study. Finally, both genetic and environmental factors, including nutrition and gut microbiota, influence the distribution of chronotypes. However, we did not include the gut microbiota or gut-derived metabolites, including trimethylamine N-oxide, in this study [17].

5. Conclusions

In summary, the current study presented the first evidence that women with PCOS with evening chronotype have worse anthropometric measurements, more severe IR, and in general follow an unhealthier lifestyle than women with PCOS with other chronotype categories. These same women have also the lowest adherence to the MD and poorest eating habits. Our results support the evidence that chronotype assessment could be a new and effective tool to screen the eating habits, and more generally the lifestyle, of women with PCOS that could be used by multidisciplinary team that usually take care of women with PCOS such as gynecologists, endocrinologists, and dietitians. Thus, chronotype assessment could be a preliminary examination to be performed in women with PCOS in order to drive the most appropriate nutritional approach.
Author Contributions: Conceptualization, L.B. and G.M.; Data curation, L.B., C.V. and G.M.; Formal analysis, L.B. and C.V.; Investigation, L.B., L.V., C.V. and G.M.; Methodology, L.B. and G.M.; Supervision, S.S. and A.C.; Validation, S.S. and A.C.; Visualization, A.C.; Writing—Original draft, L.V. and G.M.; Writing—Review and editing, L.B., L.V. and G.M. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: The study was approved by the local ethics committee (No. 05/14) and carried out in accordance with the Declaration of Helsinki for human experimentation.

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: Results attained in this study are included in the manuscript. Individual data are not publicly available due to ethical restrictions.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Wolf, W.M.; Wattick, R.A.; Kinkade, O.N.; Olfert, M.D. Geographical Prevalence of Polycystic Ovary Syndrome as Determined by Region and Race/Ethnicity. Int. J. Environ. Res. Public Health 2018, 15, 2589. [CrossRef] [PubMed]
2. Rotterdam EA-SPCWG. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil. Steril. 2004, 81, 19–25. [CrossRef] [PubMed]
3. Escobar-Morreale, H.F. Polycystic ovary syndrome: Definition, aetiology, diagnosis and treatment. Nat. Rev. Endocrinol. 2018, 14, 270–284. [CrossRef] [PubMed]
4. Gonzalez, F. Inflammation in Polycystic Ovary Syndrome: Underpinning of insulin resistance and ovarian dysfunction. Steroids 2012, 77, 300–305. [CrossRef]
5. Barrea, L.; Arnone, A.; Annunziata, G.; Muscogiuri, G.; Laudiso, D.; Salzano, C.; Pugliese, G.; Colao, A.; Savastano, S. Adherence to the Mediterranean Diet, Dietary Patterns and Body Composition in Women with Polycystic Ovary Syndrome (PCOS). Nutrients 2019, 11, 2278. [CrossRef] [PubMed]
6. Muscogiuri, G.; Policola, C.; Priotta, A.; Sorice, G.; Mezza, T.; Lassandro, A.; Della Casa, S.; Pontecorvi, A.; Giacca, A. Low levels of 25(OH)D and insulin-resistance: 2 unrelated features or a cause-effect in PCOS? Clin. Nutr. 2012, 31, 476–480. [CrossRef] [PubMed]
7. Pivonello, C.; Muscogiuri, G.; Nardone, A.; Garifalos, F.; Provvisiero, D.P.; Verde, N.; De Angelis, C.; Conforti, A.; Piscopo, M.; Auriemma, R.S.; et al. Bisphenol A: An emerging threat to female fertility. Reprod. Biol. Endocrinol. 2020, 18, 1–33. [CrossRef] [PubMed]
8. Muscogiuri, G.; Palomba, S.; Lagana, A.S.; Orío, F. Inositols in the Treatment of Insulin-Mediated Diseases. Int. J. Endocrinol. 2016, 2016, 3058393. [CrossRef]
9. Szczuko, M.; Kikut, J.; Szczuko, U.; Szydlowska, I.; Nawrocka-Rutkowska, J.; Ziôtel, M.; Verbanac, D.; Saso, L. Nutrition Strategy and Life Style in Polycystic Ovary Syndrome—Narrative Review. Nutrients 2021, 13, 2452. [CrossRef]
10. Horne, J.A.; Ostberg, O. A self-assessment questionnaire to determine morningness-eveningness in human circadian rhythms. Int. J. Chronobiol. 1976, 4, 97–110. [PubMed]
11. Munoz, J.S.G.; Canavate, R.; Hernandez, C.M.; Cara-Salmeron, V.; Morante, J.J.H. The association among chronotype, timing of food intake and food preferences depends on body mass status. Eur. J. Clin. Nutr. 2017, 71, 736–742. [CrossRef] [PubMed]
12. Muscogiuri, G.; Barrea, L.; Aprano, S.; Framondi, L.; Di Matteo, R.; Laudiso, D.; Pugliese, G.; Savastano, S.; Colao, A.; Project, O.B.O.T.O.P. Chronotype and Adherence to the Mediterranean Diet in Obesity: Results from the Opera Prevention Project. Nutrients 2020, 12, 1354. [CrossRef] [PubMed]
13. Ruiz-Lozano, T.; Vidal, J.; de Hollanda, A.; Canteras, M.; Garaulet, M.; Izquierdo-Pulido, M. Evening chronotype associates with obesity in severely obese subjects: Interaction with CLOCK 3111T/C. Int. J. Obes. 2016, 40, 1550–1557. [CrossRef]
14. Rawat, A.; Gangwar, A.K.; Tiwari, S.; Kant, S.; Garg, R.K.; Singh, P.K. Sleep quality and insulin resistance in adolescent subjects with different circadian preference: A cross-sectional study. J. Fam. Med. Prim. Care 2019, 8, 2502–2505. [CrossRef]
15. Zeng, X.; Xie, Y.J.; Liu, Y.T.; Long, S.L.; Mo, Z.C. Polycystic ovarian syndrome: Correlation between hyperandrogenism, insulin resistance and obesity. Clin. Chim. Acta 2020, 502, 214–221. [CrossRef] [PubMed]
16. Legro, R.S.; Arslanian, S.A.; Ehrmann, D.A.; Hoeger, K.M.; Murad, M.H.; Pasquali, R.; Welt, C.K. Diagnosis and Treatment of Polycystic Ovary Syndrome: An Endocrine Society Clinical Practice Guideline. J. Clin. Endocrinol. Metab. 2013, 98, 4565–4592. [CrossRef]
17. Barrea, L.; Annunziata, G.; Muscogiuri, G.; Di Somma, C.; Laudiso, D.; Maisto, M.; De Alteriis, G.; Tenore, G.C.; Colao, A.; Savastano, S. Trimethylamine-N-oxide (TMAO) as Novel Potential Biomarker of Early Predictors of Metabolic Syndrome. Nutrients 2018, 10, 1971. [CrossRef]
18. Barrea, L.; Annunziata, G.; Muscogiuri, G.; Laudiso, D.; Di Somma, C.; Maisto, M.; Tenore, G.C.; Colao, A.; Savastano, S. Trimethylamine N-oxide, Mediterranean diet, and nutrition in healthy, normal-weight adults: Also a matter of sex? Nutrition 2019, 62, 7–17. [CrossRef] [PubMed]
19. Martínez-González, M.A.; García-Arellano, A.; Toledo, E.; Salas-Salvadó, J.; Buil-Cosiales, P.; Corella, D.; Covas, M.I.; Schröder, H.; Arós, F.; Gómez-Gracia, E.; et al. A 14-Item Mediterranean Diet Assessment Tool and Obesity Indexes among High-Risk Subjects: The PREDIMED Trial. *PLoS ONE* **2012**, *7*, e43134. [CrossRef]

20. Muscogiuri, G.; Barrea, L.; Di Somma, C.; Altieri, B.; Vecchiariini, M.; Orio, F.; Spinosa, T.; Colao, A.; Savastano, S. Patient empowerment and the Mediterranean diet as a possible tool to tackle prediabetes associated with overweight or obesity: A pilot study. *Hormones* **2019**, *18*, 75–84. [CrossRef]

21. Barrea, L.; Muscogiuri, G.; Annunziata, G.; Laudisio, D.; De Alteris, G.; Tenore, G.C.; Colao, A.; Savastano, S. A New Light on Vitamin D in Obesity: A Novel Association with Trimethylamine-N-Oxide (TMAO). *Nutrients* **2019**, *11*, 1310. [CrossRef] [PubMed]

22. Savanelli, M.C.; Scarano, E.; Muscogiuri, G.; Barrea, L.; Vuolo, L.; Rubino, M.; Savastano, S.; Colao, A.; Di Somma, C. Cardiovascular risk in adult hypopituitaric patients with growth hormone deficiency: Is there a role for vitamin D? *Endocrine* **2016**, *52*, 111–119. [CrossRef] [PubMed]

23. WHO. Body Mass Index. Available online: http://www.euro.who.int/en/health-topics/disease-prevention/nutrition/a-healthy-lifestyle/body-mass-index-bmi (accessed on 10 September 2021).

24. CDC. Anthropometry Procedures Manual. Available online: http://www.cdc.gov/nchs/data/nhanes/nhanes_11_12_Anthropometry_Procedures_Manual.pdf (accessed on 10 September 2021).

25. Matthews, D.R.; Hosker, J.P.; Rudenski, A.S.; Naylor, B.A.; Treacher, D.F.; Turner, R.C. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. *Diabetologia* **1985**, *28*, 412–419. [CrossRef]

26. Garaulet, M.; Lee, Y.-C.; Shen, J.; Parnell, L.D.; Arnett, D.K.; Tsai, M.Y.; Lai, C.-Q.; Ordovas, J.M. CLOCK genetic variation and metabolic syndrome risk: Modulation by the PREDIMED randomized trial. *Cardiovasc. Diabetol.* **2016**, *15*, 4. [CrossRef] [PubMed]

27. Garcia-Rios, A.; Gomez-Delgado, F.J.; Garaulet, M.; Alcala-Diaz, J.F.; Delgado-Lista, F.J.; Marin, C.; Rangel-Zuñiga, O.A.; Rodríguez-Cantalejo, F.; Gomez-Luna, P.; Ordovas, J.M.; et al. Beneficial effect of CLOCK gene polymorphism rs1801260 in combination with low-fat diet on insulin metabolism in the patients with metabolic syndrome. *Chronic Biol. Int.* **2014**, *31*, 401–408. [CrossRef]

28. Dupuis, J.; Langenberg, C.; Prokopenko, I.; Saxena, R.; Soranzo, N.; Jackson, A.U.; Wheeler, E.; Glazer, N.L.; Bouatia-Naji, N.; Masi-Gluth, C.; et al. Changes of Dietary Fat and Carbohydrate Content Alter Central and Peripheral Clock in Humans. *PLoS ONE* **2014**, *9*, e104065. [CrossRef]

29. García-Rios, A.; Gomez-Delgado, F.J.; Garaulet, M.; Alcala-Diaz, J.F.; Delgado-Lista, F.J.; Marin, C.; Rangel-Zuñiga, O.A.; Rodríguez-Cantalejo, F.; Gomez-Luna, P.; Ordovas, J.M.; et al. Beneficial effect of CLOCK gene polymorphism rs1801260 in combination with low-fat diet on insulin metabolism in the patients with metabolic syndrome. *Chronic Biol. Int.* **2014**, *31*, 401–408. [CrossRef]

30. Gontijo, C.A.; Cabral, B.B.M.; Balieiro, L.C.T.; Teixeira, G.P.; Fahmy, W.M.; Maia, Y.C.D.P.; Crispim, C.A. Time-related eating patterns and chronotype are associated with diet quality in pregnant women. *Chronicobiol. Int.* **2018**, *36*, 75–84. [CrossRef]

31. Martínez-González, M.A.; García-Arellano, A.; Toledo, E.; Salas-Salvadó, J.; Buil-Cosiales, P.; Corella, D.; Covas, M.I.; Schröder, H.; Arós, F.; Gómez-Gracia, E.; et al. A 14-Item Mediterranean Diet Assessment Tool and Obesity Indexes among High-Risk Subjects: The PREDIMED Trial. *PLoS ONE* **2012**, *7*, e43134. [CrossRef]

32. Mota, M.C.; Waterhouse, J.; De-Souza, D.A.; Rossato, L.T.; Silva, C.M.; Araújo, M.B.J.; Tufik, S.; de Mello, M.T.; Crispim, C.A. Time-related eating patterns and chronotype are associated with diet quality in pregnant women. *Chronicobiol. Int.* **2018**, *36*, 75–84. [CrossRef]

33. Muscogiuri, G.; Barrea, L.; Aprano, S.; Framondi, L.; Lapetra, J.; Castañer, O.; Arós, F.; Garaulet, M.;; Corella, D.; Asensio, E.M.; Coltell, O.; Sorlí, J.V.; Estruch, R.; Martínez-González, M.; Salas-Salvadó, J.;; Csókay, K.;; Lleonart, M.;; Lapetra, J.; et al. CLOCK gene variation is associated with incidence of type-2 diabetes and cardiovascular diseases in type-2 diabetic subjects: Dietary modulation in the PREDIMED randomized trial. *Cardiovasc. Diabetol.* **2016**, *15*, 4. [CrossRef] [PubMed]

34. Muscogiuri, G.; Barrea, L.; Di Somma, C.; Altieri, B.; Vecchiariini, M.; Orio, F.; Spinosa, T.; Colao, A.; Savastano, S. A New Light on Vitamin D in Obesity: A Novel Association with Trimethylamine-N-Oxide (TMAO). *Nutrients* **2019**, *11*, 1310. [CrossRef] [PubMed]

35. Muscogiuri, G.; Barrea, L.; Di Somma, C.; Altieri, B.; Vecchiariini, M.; Orio, F.; Spinosa, T.; Colao, A.; Savastano, S. A New Light on Vitamin D in Obesity: A Novel Association with Trimethylamine-N-Oxide (TMAO). *Nutrients* **2019**, *11*, 1310. [CrossRef] [PubMed]

36. Muscogiuri, G.; Barrea, L.; Aprano, S.; Framondi, L.; Di Matteo, R.; Laudisio, D.; Pugliese, G.; Savastano, S.; Colao, A. A New Light on Vitamin D in Obesity: A Novel Association with Trimethylamine-N-Oxide (TMAO). *Nutrients* **2019**, *11*, 1310. [CrossRef] [PubMed]

37. Muscogiuri, G.; Barrea, L.; Aprano, S.; Framondi, L.; Di Matteo, R.; Laudisio, D.; Pugliese, G.; Savastano, S.; Colao, A. A New Light on Vitamin D in Obesity: A Novel Association with Trimethylamine-N-Oxide (TMAO). *Nutrients* **2019**, *11*, 1310. [CrossRef] [PubMed]

38. Muscogiuri, G.; Barrea, L.; Di Somma, C.; Altieri, B.; Vecchiariini, M.; Orio, F.; Spinosa, T.; Colao, A.; Savastano, S. A New Light on Vitamin D in Obesity: A Novel Association with Trimethylamine-N-Oxide (TMAO). *Nutrients* **2019**, *11*, 1310. [CrossRef] [PubMed]

39. Muscogiuri, G.; Barrea, L.; Aprano, S.; Framondi, L.; Di Matteo, R.; Laudisio, D.; Pugliese, G.; Savastano, S.; Colao, A. A New Light on Vitamin D in Obesity: A Novel Association with Trimethylamine-N-Oxide (TMAO). *Nutrients* **2019**, *11*, 1310. [CrossRef] [PubMed]

40. Muscogiuri, G.; Barrea, L.; Aprano, S.; Framondi, L.; Di Matteo, R.; Laudisio, D.; Pugliese, G.; Savastano, S.; Colao, A. A New Light on Vitamin D in Obesity: A Novel Association with Trimethylamine-N-Oxide (TMAO). *Nutrients* **2019**, *11*, 1310. [CrossRef] [PubMed]
41. Trichopoulou, A.; Vasilopoulou, E. Mediterranean diet and longevity. *Br. J. Nutr.* 2000, 84 (Suppl. 2), S205–S209. [CrossRef] [PubMed]

42. Gangwisch, J.; Hale, L.; St-Onge, M.-P.; Choi, L.; LeBlanc, E.S.; Malaspina, D.; Opler, M.G.; Shadyab, A.H.; Shikany, J.M.; Snetselaar, L.; et al. High glycemic index and glycemic load diets as risk factors for insomnia: Analyses from the Women’s Health Initiative. *Am. J. Clin. Nutr.* 2019, 111, 429–439. [CrossRef]

43. St-Onge, M.P.; Roberts, A.; Shechter, A.; Choudhury, A.R. Fiber and Saturated Fat Are Associated with Sleep Arousals and Slow Wave Sleep. *J. Clin. Sleep Med.* 2016, 12, 19–24. [CrossRef] [PubMed]

44. Muscogiuri, G.; Barrea, L.; Annunziata, G.; Di Somma, C.; Laudisio, D.; Colao, A.; Savastano, S. Obesity and sleep disturbance: The chicken or the egg? *Crit. Rev. Food Sci. Nutr.* 2019, 59, 2158–2165. [CrossRef]

45. Tanaka, E.; Yatsuya, H.; Uemura, M.; Murata, C.; Otsuka, R.; Toyoshima, H.; Tamakoshi, K.; Sasaki, S.; Kawaguchi, L.; Aoyama, A. Associations of Protein, Fat, and Carbohydrate Intakes With Insomnia Symptoms Among Middle-aged Japanese Workers. *J. Epidemiol.* 2013, 23, 132–138. [CrossRef] [PubMed]

46. Hudson, C.; Hudson, S.P.; Hecht, T.; MacKenzie, J. Protein source tryptophan versus pharmaceutical grade tryptophan as an efficacious treatment for chronic insomnia. *Nutr. Neurosci.* 2005, 8, 121–127. [CrossRef] [PubMed]

47. Arnulf, I.; Quintin, P.; Alvarez, J.C.; Vigil, L.; Touitou, Y.; Lèbre, A.-S.; Bellenger, A.; Varoquaux, O.; Derenne, J.-P.; Allilaire, J.-F.; et al. Mid-morning Tryptophan Depletion Delays REM Sleep Onset in Healthy Subjects. *Neuropsychopharmacology* 2002, 27, 843–851. [CrossRef]

48. Bhatti, T.; Gillin, J.; Seifritz, E.; Moore, P.; Clark, C.; Golshan, S.; Stahl, S.; Rapaport, M.; Kelsoe, J. Effects of a Tryptophan-Free Amino Acid Drink Challenge on Normal Human Sleep Electroencephalogram and Mood. *Biol. Psychiatry* 1998, 43, 52–59. [CrossRef]

49. Milagres, M.P.; Minim, V.P.; Minim, L.A.; Simiqueli, A.A.; Moraes, L.E.; Martino, H.S. Night milking adds value to cow’s milk. *J. Sci. Food Agric.* 2014, 94, 1688–1692. [CrossRef] [PubMed]

50. Lin, H.H.; Tsai, P.S.; Fang, S.C.; Liu, J.F. Effect of kiwifruit consumption on sleep quality in adults with sleep problems. *Asia Pac. J. Clin. Nutr.* 2011, 20, 169–174.

51. Pigeon, W.R.; Carr, M.; Gorman, C.; Perlis, M.L. Effects of a tart cherry juice beverage on the sleep of older adults with insomnia: A pilot study. *J. Med. Food* 2010, 13, 579–583. [CrossRef]

52. Garrido, M.; Paredes, S.D.; Cubero, J.; Lozano, M.; Toribio-Delgado, A.F.; Muñoz, J.L.; Reiter, R.J.; Barriga, C.; Rodríguez, A.B. Jerte Valley Cherry-Enriched Diets Improve Nocturnal Rest and Increase 6-Sulfatoxymelatonin and Total Antioxidant Capacity in the Urine of Middle-Aged and Elderly Humans. *J. Gerontol. Ser. A* 2010, 65A, 909–914. [CrossRef]

53. Ribas-Latre, A.; Baselga-Escudero, L.; Casanova, E.; Arola-Arnal, A.; Aujard, F. Chronic consumption of dietary proanthocyanidins modulates peripheral clocks in healthy and obese rats. *J. Nutr. Biochem.* 2015, 26, 112–119. [CrossRef] [PubMed]

54. Pifferi, F.; Rahman, A.; Languille, S.; Auffret, A.; Babiloni, C.; Blin, O.; Lamberty, Y.; Richardson, J.C.; Atrooz, F.; Salim, S. Sleep deprivation, oxidative stress and inflammation. *Adv. Protein Chem. Struct. Biol.* 2020, 119, 309–336. [PubMed]

55. Atrooz, F.; Salim, S. Sleep deprivation, oxidative stress and inflammation. *Adv. Protein Chem. Struct. Biol.* 2020, 119, 309–336. [PubMed]

56. Ramis, M.R.; Esteban, S.; Miralles, A.; Tan, D.X.; Reiter, R.J. Caloric restriction, resveratrol and melatonin: Role of SIRT1 and implications for aging and related-diseases. *Mech. Ageing Dev.* 2015, 146, 28–41. [CrossRef]

57. Asher, G.; Gatfield, D.; Stratmann, M.; Reinke, H.; Dibner, C.; Kreppel, F.; Mostoslavsky, R.; Alt, F.W.; Schibler, U. SIRT1 Regulates Circadian Clock Gene Expression through PER2 Deacetylation. *Cell* 2008, 134, 317–328. [CrossRef] [PubMed]

58. Skrlec, I.; Milic, J.; Heffer, M.; Wagner, J.; Peterlin, B. Circadian clock genes and circadian phenotypes in patients with myocardial infarction. *Adv. Med. Sci.* 2019, 64, 224–229. [CrossRef] [PubMed]